{"protocolSection": {"identificationModule": {"nctId": "NCT03877237", "orgStudyIdInfo": {"id": "D169EC00002"}, "secondaryIdInfos": [{"id": "2018-003442-16", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction", "officialTitle": "International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Reduced Ejection Fraction"}, "statusModule": {"statusVerifiedDate": "2021-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-04-09", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-03-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-03-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-02-21", "studyFirstSubmitQcDate": "2019-03-14", "studyFirstPostDateStruct": {"date": "2019-03-15", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2021-03-04", "resultsFirstSubmitQcDate": "2021-04-12", "resultsFirstPostDateStruct": {"date": "2021-05-05", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-04-12", "lastUpdatePostDateStruct": {"date": "2021-05-05", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)"}, "conditionsModule": {"conditions": ["Heart Failure With Reduced Ejection Fraction (HFrEF)"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 313, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Dapagliflozin", "type": "EXPERIMENTAL", "description": "Green, diamond shaped, film coated tablets 10 mg administered orally, once daily", "interventionNames": ["Drug: Dapagliflozin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Green, diamond shaped, film coated tablets placebo administered orally, once daily", "interventionNames": ["Other: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Dapagliflozin", "description": "Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.", "armGroupLabels": ["Dapagliflozin"]}, {"type": "OTHER", "name": "Placebo", "description": "Tablets administered orally once daily. Treatment start within 24h after randomisation for 16 weeks.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden).", "description": "Change from baseline in KCCQ-TSS was defined as the endpoint value at week 16 minus the baseline value. KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ-TSS incorporates the symptom frequency (4 items) and symptom burden (3 items) domains into a single summary score. The score is transformed to a range of 0-100, in which a higher score reflects better health status. Baseline value is the last value on or prior to the randomization visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive. In rank ANCOVA and HL estimation, multiple imputation was performed on missing values for participants who were alive at the visit at week 16 but did not have KCCQ-TSS values.", "timeFrame": "At baseline and at week 16 or death before week 16"}, {"measure": "Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Physical Limitation Score (KCCQ-PLS) at Week 16 (Higher Scores Represent Less Physical Limitation Due to HF)", "description": "Change from baseline in KCCQ-PLS was defined as the endpoint value at week 16 minus the baseline value. KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ-PLS incorporates the 6 physical limitation items into a single score. The score is transformed to a range of 0-100, in which a higher score reflects better health status. Baseline value is the last value on or prior to the randomization visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive. In rank ANCOVA and HL estimation, multiple imputation was performed on missing values for participants who were alive at the visit at week 16 but did not have KCCQ-PLS values.", "timeFrame": "At baseline and at week 16 or death before week 16"}, {"measure": "Change From Baseline in 6-minute Walk Distance (6MWD) at Week 16 (Larger Distances Represent Better Functional Capacity).", "description": "Change from baseline in 6-minute walk distance (6MWD) (exercise capacity) at week 16 was defined as the distance walked in 6 minutes at week 16 minus the baseline value. Baseline value is the last value on or prior to the randomization visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive. In rank ANCOVA and HL estimation, multiple imputation was performed on missing values for participants who were alive at the visit at week 16 but did not have 6MWD values.", "timeFrame": "At baseline and at week 16 or death prior to week 16"}], "secondaryOutcomes": [{"measure": "Change From Baseline at the End of the Study in the Total Time Spent in Light to Vigorous Physical Activity, as Assessed Using a Wearable Activity Monitor (Accelerometer).", "description": "Change from baseline at the end of the study in total time spent in light to vigorous physical activity (LVPA), as assessed using a wearable activity monitor, was defined as the total time \\[per day\\] spent in LVPA at the end of the study minus the baseline value. Baseline is the 7 day period starting on the day of enrolment and ending before randomization. End of study is defined as the period starting on the day of week 14 and prior to the week 16 visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive.", "timeFrame": "At baseline and at end of study or death before week 16."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Provision of signed informed consent prior to any study specific procedures\n* Male or female, aged \u226518 years\n* Documented diagnosis of symptomatic HFrEF (NYHA functional class II-IV), which has been present for at least 8 weeks\n* LVEF\u226440%\n* Elevated NT-proBNP levels\n* Patients should receive background standard of care as described below: All HFrEF patients should be treated according to locally recognised guidelines on standard of care treatment with both drugs and devices, as appropriate. Guideline-recommended medications should be used at recommended doses unless contraindicated or not tolerated. Therapy should have been individually optimised and stable for \u22654 weeks (this does not apply to diuretics) before visit 1 and include (unless contraindicated or not tolerated):\n\n  * an ACE inhibitor, or ARB or sacubitril/valsartan and\n  * a beta-blocker and\n  * if considered appropriate by the patient's treating physician; a mineral corticoid receptor antagonist\n* 6MWD\u2265100 metres and \u2264425 metres at enrolment and randomization.\n\nExclusion Criteria:\n\n* Presence of any condition that precludes exercise testing\n* Participation in a structured exercise training programme in the 1 month prior to screening or planned to start during the trial\n* Receiving therapy with an SGLT2 inhibitor within 4 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor\n* Type 1 diabetes mellitus\n* eGFR \\<25 mL/min/1.73 m2 (CKD-EPI formula) at enrolment, unstable or rapidly progressing renal disease at time of randomisation\n* Systolic BP \\<95 mmHg on 2 consecutive measurements\n* Systolic BP \u2265160 mmHg if not on treatment with \u22653 blood pressure lowering medications or \u2265180 mmHg irrespective of treatments, on 2 consecutive measurements\n* Current acute decompensated HF or hospitalisation due to decompensated HF \\<4 weeks prior to enrolment\n* MI, unstable angina, coronary revascularization ablation of atrial flutter/fibrillation, valve repair/replacement, implantation of a cardiac resynchronization therapy device within 12 weeks prior to enrolment or planned to undergo any of these operations after randomization.\n* Stroke or transient ischemic attack within 12 weeks prior to enrolment.\n* Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease including COPD.\n* Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after randomization\n* HF due to infiltrative cardiomyopathy, active myocarditis, constrictive pericarditis, cardiac tamponade, known genetic hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia, or uncorrected primary valvular disease", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "150 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"facility": "Research Site", "city": "Alexander City", "state": "Alabama", "zip": "35010", "country": "United States", "geoPoint": {"lat": 32.94401, "lon": -85.95385}}, {"facility": "Research Site", "city": "Fairhope", "state": "Alabama", "zip": "36532", "country": "United States", "geoPoint": {"lat": 30.52297, "lon": -87.90333}}, {"facility": "Research Site", "city": "Fort Payne", "state": "Alabama", "zip": "35967", "country": "United States", "geoPoint": {"lat": 34.44425, "lon": -85.71969}}, {"facility": "Research Site", "city": "Mobile", "state": "Alabama", "zip": "36608", "country": "United States", "geoPoint": {"lat": 30.69436, "lon": -88.04305}}, {"facility": "Research Site", "city": "Beverly Hills", "state": "California", "zip": "90211", "country": "United States", "geoPoint": {"lat": 34.07362, "lon": -118.40036}}, {"facility": "Research Site", "city": "Torrance", "state": "California", "zip": "90502", "country": "United States", "geoPoint": {"lat": 33.83585, "lon": -118.34063}}, {"facility": "Research Site", "city": "Stamford", "state": "Connecticut", "zip": "06905", "country": "United States", "geoPoint": {"lat": 41.05343, "lon": -73.53873}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33133", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Miami", "state": "Florida", "zip": "33173", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Research Site", "city": "Tucker", "state": "Georgia", "zip": "30084", "country": "United States", "geoPoint": {"lat": 33.85455, "lon": -84.21714}}, {"facility": "Research Site", "city": "Munster", "state": "Indiana", "zip": "46321", "country": "United States", "geoPoint": {"lat": 41.56448, "lon": -87.51254}}, {"facility": "Research Site", "city": "Petoskey", "state": "Michigan", "zip": "49770", "country": "United States", "geoPoint": {"lat": 45.37334, "lon": -84.95533}}, {"facility": "Research Site", "city": "Kansas City", "state": "Missouri", "zip": "64111", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Research Site", "city": "New Brunswick", "state": "New Jersey", "zip": "08901", "country": "United States", "geoPoint": {"lat": 40.48622, "lon": -74.45182}}, {"facility": "Research Site", "city": "Buffalo", "state": "New York", "zip": "14215", "country": "United States", "geoPoint": {"lat": 42.88645, "lon": -78.87837}}, {"facility": "Research Site", "city": "New York", "state": "New York", "zip": "10001", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Research Site", "city": "Rosedale", "state": "New York", "zip": "11422", "country": "United States", "geoPoint": {"lat": 40.66205, "lon": -73.73541}}, {"facility": "Research Site", "city": "Burlington", "state": "North Carolina", "zip": "27215", "country": "United States", "geoPoint": {"lat": 36.09569, "lon": -79.4378}}, {"facility": "Research Site", "city": "Abington", "state": "Pennsylvania", "zip": "19001", "country": "United States", "geoPoint": {"lat": 40.12067, "lon": -75.11795}}, {"facility": "Research Site", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15212", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Research Site", "city": "Tullahoma", "state": "Tennessee", "zip": "37388", "country": "United States", "geoPoint": {"lat": 35.36202, "lon": -86.20943}}, {"facility": "Research Site", "city": "Falls Church", "state": "Virginia", "zip": "22042", "country": "United States", "geoPoint": {"lat": 38.88233, "lon": -77.17109}}, {"facility": "Research Site", "city": "Seattle", "state": "Washington", "zip": "98101", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Research Site", "city": "Blumenau", "zip": "89020-430", "country": "Brazil", "geoPoint": {"lat": -26.91944, "lon": -49.06611}}, {"facility": "Research Site", "city": "Porto Alegre", "zip": "91350-200", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Research Site", "city": "Sao Paulo", "zip": "01141-020", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Research Site", "city": "S\u00e3o Paulo", "zip": "05403-000", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Research Site", "city": "Winnipeg", "state": "Manitoba", "zip": "R2H 2A6", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "Research Site", "city": "Moncton", "state": "New Brunswick", "zip": "E1G 1A7", "country": "Canada", "geoPoint": {"lat": 46.09454, "lon": -64.7965}}, {"facility": "Research Site", "city": "St. John's", "state": "Newfoundland and Labrador", "zip": "A1B 3V6", "country": "Canada", "geoPoint": {"lat": 47.56494, "lon": -52.70931}}, {"facility": "Research Site", "city": "Ajax", "state": "Ontario", "zip": "L1Z 0B1", "country": "Canada", "geoPoint": {"lat": 43.85012, "lon": -79.03288}}, {"facility": "Research Site", "city": "North York", "state": "Ontario", "zip": "M3M 3E5", "country": "Canada", "geoPoint": {"lat": 43.76681, "lon": -79.4163}}, {"facility": "Research Site", "city": "Oshawa", "state": "Ontario", "zip": "L1J 2K1", "country": "Canada", "geoPoint": {"lat": 43.90012, "lon": -78.84957}}, {"facility": "Research Site", "city": "Scarborough", "state": "Ontario", "zip": "M1E 5E9", "country": "Canada", "geoPoint": {"lat": 43.77223, "lon": -79.25666}}, {"facility": "Research Site", "city": "Stoney Creek", "state": "Ontario", "zip": "L8J 3W2", "country": "Canada"}, {"facility": "Research Site", "city": "York", "state": "Ontario", "zip": "M9N 1W4", "country": "Canada"}, {"facility": "Research Site", "city": "Gatineau", "state": "Quebec", "zip": "J8Y 6S8", "country": "Canada", "geoPoint": {"lat": 45.47723, "lon": -75.70164}}, {"facility": "Research Site", "city": "Longueuil", "state": "Quebec", "zip": "J4M 2X1", "country": "Canada", "geoPoint": {"lat": 45.53121, "lon": -73.51806}}, {"facility": "Research Site", "city": "Montreal", "state": "Quebec", "zip": "H2X 0A9", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "Research Site", "city": "St-Georges", "state": "Quebec", "zip": "G5Y 4T8", "country": "Canada", "geoPoint": {"lat": 46.11353, "lon": -70.66526}}, {"facility": "Research Site", "city": "Quebec", "zip": "G1G 3Z4", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Quebec", "zip": "G2J 0C4", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Quebec", "zip": "G3K 2P8", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "Research Site", "city": "Esbjerg", "zip": "6700", "country": "Denmark", "geoPoint": {"lat": 55.47028, "lon": 8.45187}}, {"facility": "Research Site", "city": "Hellerup", "zip": "2900", "country": "Denmark", "geoPoint": {"lat": 55.73204, "lon": 12.57093}}, {"facility": "Research Site", "city": "Hj\u00f8rring", "zip": "9800", "country": "Denmark", "geoPoint": {"lat": 57.46417, "lon": 9.98229}}, {"facility": "Research Site", "city": "Hvidovre", "zip": "2650", "country": "Denmark", "geoPoint": {"lat": 55.65719, "lon": 12.47364}}, {"facility": "Research Site", "city": "K\u00f8benhavn", "zip": "2300", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "Research Site", "city": "N\u00e6stved", "zip": "4700", "country": "Denmark", "geoPoint": {"lat": 55.22992, "lon": 11.76092}}, {"facility": "Research Site", "city": "Odense C", "zip": "5000", "country": "Denmark", "geoPoint": {"lat": 55.39594, "lon": 10.38831}}, {"facility": "Research Site", "city": "Randers", "zip": "8930", "country": "Denmark", "geoPoint": {"lat": 56.4607, "lon": 10.03639}}, {"facility": "Research Site", "city": "Svendborg", "zip": "DK-5700", "country": "Denmark", "geoPoint": {"lat": 55.05982, "lon": 10.60677}}, {"facility": "Research Site", "city": "\u00c5rhus N", "zip": "8200", "country": "Denmark", "geoPoint": {"lat": 56.15674, "lon": 10.21076}}, {"facility": "Research Site", "city": "Daito-shi", "zip": "574-0074", "country": "Japan"}, {"facility": "Research Site", "city": "Kobe-shi", "zip": "654-0155", "country": "Japan", "geoPoint": {"lat": 34.6913, "lon": 135.183}}, {"facility": "Research Site", "city": "Matsubara-shi", "zip": "580-0032", "country": "Japan", "geoPoint": {"lat": 34.56667, "lon": 135.55}}, {"facility": "Research Site", "city": "Naha", "zip": "902-8511", "country": "Japan", "geoPoint": {"lat": 26.21667, "lon": 127.68333}}, {"facility": "Research Site", "city": "Osaka-shi", "zip": "530-0001", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "Research Site", "city": "Sayama-shi,", "zip": "350-1305", "country": "Japan", "geoPoint": {"lat": 35.85295, "lon": 139.41212}}, {"facility": "Research Site", "city": "Shunan-shi", "zip": "745-0822", "country": "Japan", "geoPoint": {"lat": 34.08053, "lon": 131.82564}}, {"facility": "Research Site", "city": "Takarazuka-shi", "zip": "665-0873", "country": "Japan", "geoPoint": {"lat": 34.79936, "lon": 135.35697}}, {"facility": "Research Site", "city": "Gangwon-do", "zip": "26426", "country": "Korea, Republic of"}, {"facility": "Research Site", "city": "Seoul", "zip": "03080", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Seoul", "zip": "03722", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Research Site", "city": "Lucenec", "zip": "984 01", "country": "Slovakia", "geoPoint": {"lat": 48.33249, "lon": 19.66708}}, {"facility": "Research Site", "city": "Martin", "zip": "036 01", "country": "Slovakia", "geoPoint": {"lat": 49.06651, "lon": 18.92399}}, {"facility": "Research Site", "city": "Presov", "zip": "080 01", "country": "Slovakia", "geoPoint": {"lat": 48.99839, "lon": 21.23393}}, {"facility": "Research Site", "city": "Cape Town", "zip": "7405", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Research Site", "city": "Cape Town", "zip": "7500", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Research Site", "city": "Diepkloof, Soweto", "zip": "2013", "country": "South Africa"}, {"facility": "Research Site", "city": "G\u00f6teborg", "zip": "413 45", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "Research Site", "city": "Lund", "zip": "222 21", "country": "Sweden", "geoPoint": {"lat": 55.70584, "lon": 13.19321}}, {"facility": "Research Site", "city": "Ostersund", "zip": "831 83", "country": "Sweden", "geoPoint": {"lat": 63.1792, "lon": 14.63566}}, {"facility": "Research Site", "city": "Stockholm", "zip": "114 46", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "Research Site", "city": "Stockholm", "zip": "118 83", "country": "Sweden", "geoPoint": {"lat": 59.33258, "lon": 18.0649}}, {"facility": "Research Site", "city": "Ume\u00e5", "zip": "90737", "country": "Sweden", "geoPoint": {"lat": 63.82842, "lon": 20.25972}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "redacted Clinical Study Protocol (CSP)", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169EC00002&amp;attachmentIdentifier=d63ceb7a-2a2d-4a96-9adb-722a4237ce11&amp;fileName=d169ec00002-csp-v2_Redacted.pdf&amp;versionIdentifier="}, {"label": "redacted Statistical Analysis Plan (SAP)", "url": "https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D169EC00002&amp;attachmentIdentifier=7c255e2c-42d1-4f94-85b7-3724c96b4c0e&amp;fileName=d169ec00002-sap-ed-3_Redacted.pdf&amp;versionIdentifier="}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Dapa 10mg", "description": "Dapagliflozin 10 mg, given once daily per oral use."}, {"id": "FG001", "title": "Placebo", "description": "Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "156"}, {"groupId": "FG001", "numSubjects": "157"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "156"}, {"groupId": "FG001", "numSubjects": "157"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "151"}, {"groupId": "FG001", "numSubjects": "151"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Full Analysis Set: All participants that were randomized, regardless of whether treated or not.", "groups": [{"id": "BG000", "title": "Dapa 10mg", "description": "Dapagliflozin 10 mg, given once daily per oral use."}, {"id": "BG001", "title": "Placebo", "description": "Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "156"}, {"groupId": "BG001", "value": "157"}, {"groupId": "BG002", "value": "313"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "68.4", "spread": "9.84"}, {"groupId": "BG001", "value": "67.3", "spread": "10.95"}, {"groupId": "BG002", "value": "67.8", "spread": "10.41"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "80"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "111"}, {"groupId": "BG001", "value": "122"}, {"groupId": "BG002", "value": "233"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "39"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "138"}, {"groupId": "BG001", "value": "136"}, {"groupId": "BG002", "value": "274"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "White", "measurements": [{"groupId": "BG000", "value": "100"}, {"groupId": "BG001", "value": "98"}, {"groupId": "BG002", "value": "198"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "47"}]}, {"title": "Native Hawaiian or other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "46"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "22"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden).", "description": "Change from baseline in KCCQ-TSS was defined as the endpoint value at week 16 minus the baseline value. KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ-TSS incorporates the symptom frequency (4 items) and symptom burden (3 items) domains into a single summary score. The score is transformed to a range of 0-100, in which a higher score reflects better health status. Baseline value is the last value on or prior to the randomization visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive. In rank ANCOVA and HL estimation, multiple imputation was performed on missing values for participants who were alive at the visit at week 16 but did not have KCCQ-TSS values.", "populationDescription": "Full Analysis Set: All participants that were randomized, regardless of whether treated or not.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Score on a scale", "timeFrame": "At baseline and at week 16 or death before week 16", "groups": [{"id": "OG000", "title": "Dapa 10mg", "description": "Dapagliflozin 10 mg, given once daily per oral use."}, {"id": "OG001", "title": "Placebo", "description": "Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "157"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.08", "lowerLimit": "-4.17", "upperLimit": "14.58"}, {"groupId": "OG001", "value": "0.00", "lowerLimit": "-10.42", "upperLimit": "9.38"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "For the primary efficacy endpoint KCCQ-TSS, the following hypothesis was tested using the significance level 0.04990\n\n* H0: m(r(A)) = m(r(C)) versus\n* H1: m(r(A)) \u2260 m(r(C)) Where H0 and H1 are the null and alternative hypotheses, respectively, and m(r(A)) and m(r(C)) represent the median of the ranked changes in the primary efficacy endpoint, KCCQ-TSS, from baseline to week 16, among patients receiving dapagliflozin (Active) and placebo (Control) treatment, respectively.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.02164", "pValueComment": "To account for multiplicity, a pre-specified testing strategy was followed to control the overall type I error rate.", "statisticalMethod": "Rank ANCOVA", "statisticalComment": "Model includes baseline rank of outcome variable as a covariate, treatment group as a factor, and is stratified by T2DM status at randomization.", "paramType": "Hodges-Lehmann median diff. vs placebo", "paramValue": "4.23", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.96", "ciUpperLimit": "8.22"}]}, {"type": "PRIMARY", "title": "Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Physical Limitation Score (KCCQ-PLS) at Week 16 (Higher Scores Represent Less Physical Limitation Due to HF)", "description": "Change from baseline in KCCQ-PLS was defined as the endpoint value at week 16 minus the baseline value. KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ-PLS incorporates the 6 physical limitation items into a single score. The score is transformed to a range of 0-100, in which a higher score reflects better health status. Baseline value is the last value on or prior to the randomization visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive. In rank ANCOVA and HL estimation, multiple imputation was performed on missing values for participants who were alive at the visit at week 16 but did not have KCCQ-PLS values.", "populationDescription": "Full Analysis Set: All participants that were randomized, regardless of whether treated or not, excluding participants with non-calculable baseline or week 16 KCCQ-PLS.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Score on a scale", "timeFrame": "At baseline and at week 16 or death before week 16", "groups": [{"id": "OG000", "title": "Dapa 10mg", "description": "Dapagliflozin 10 mg, given once daily per oral use."}, {"id": "OG001", "title": "Placebo", "description": "Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "153"}, {"groupId": "OG001", "value": "156"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.17", "lowerLimit": "-4.17", "upperLimit": "12.50"}, {"groupId": "OG001", "value": "0.00", "lowerLimit": "-8.33", "upperLimit": "8.33"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "For the primary efficacy endpoint KCCQ-PLS, the following hypothesis was tested at significant level of 0.04990\n\n* H0: m(r(A)) = m(r(C)) versus\n* H1: m(r(A)) \u2260 m(r(C)) Where H0 and H1 are the null and alternative hypotheses, respectively, and m(r(A)) and m(r(C)) represent the median of the ranked changes in the primary efficacy endpoint, KCCQ-PLS, from baseline to week 16, among patients receiving dapagliflozin (Active) and placebo (Control) treatment, respectively.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.05842", "pValueComment": "KCCQ-PLS was tested at the alpha level of 0.04990 because KCCQ-TSS had a statistically significant p-value, in accordance with the pre-specified testing strategy.", "statisticalMethod": "Rank ANCOVA", "statisticalComment": "Model includes baseline rank of outcome variable as a covariate, treatment group as a factor, and is stratified by T2DM status at randomization.", "paramType": "Hodges-Lehmann median diff. vs placebo", "paramValue": "4.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.03", "ciUpperLimit": "8.33"}]}, {"type": "PRIMARY", "title": "Change From Baseline in 6-minute Walk Distance (6MWD) at Week 16 (Larger Distances Represent Better Functional Capacity).", "description": "Change from baseline in 6-minute walk distance (6MWD) (exercise capacity) at week 16 was defined as the distance walked in 6 minutes at week 16 minus the baseline value. Baseline value is the last value on or prior to the randomization visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive. In rank ANCOVA and HL estimation, multiple imputation was performed on missing values for participants who were alive at the visit at week 16 but did not have 6MWD values.", "populationDescription": "Full Analysis Set: All participants that were randomized, regardless of whether treated or not.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "meters", "timeFrame": "At baseline and at week 16 or death prior to week 16", "groups": [{"id": "OG000", "title": "Dapa 10mg", "description": "Dapagliflozin 10 mg, given once daily per oral use."}, {"id": "OG001", "title": "Placebo", "description": "Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "156"}, {"groupId": "OG001", "value": "157"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.0", "lowerLimit": "-2.0", "upperLimit": "42.0"}, {"groupId": "OG001", "value": "13.5", "lowerLimit": "-12.5", "upperLimit": "46.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "For the primary efficacy endpoint 6MWD, the following hypothesis was tested using the significance level 0.00010:\n\nH0: m(r(A)) = m(r(C)) versus H1: m(r(A)) \u2260 m(r(C)) Where H0 and H1 are the null and alternative hypotheses, respectively, and m(r(A)) and m(r(C)) represent the median of the ranked changes in the primary efficacy endpoint, 6MWD, from baseline to week 16, among patients receiving dapagliflozin (Active) and placebo (Control) treatment, respectively.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.68626", "pValueComment": "To account for multiplicity, a pre-specified testing strategy was followed to control the overall type I error rate.", "statisticalMethod": "Rank ANCOVA", "statisticalComment": "Model includes baseline rank of outcome variable as a covariate, treatment group as a factor, and is stratified by T2DM status at randomization.", "paramType": "Hodges-Lehmann median diff. vs placebo", "paramValue": "3.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.5", "ciUpperLimit": "13.0"}]}, {"type": "SECONDARY", "title": "Change From Baseline at the End of the Study in the Total Time Spent in Light to Vigorous Physical Activity, as Assessed Using a Wearable Activity Monitor (Accelerometer).", "description": "Change from baseline at the end of the study in total time spent in light to vigorous physical activity (LVPA), as assessed using a wearable activity monitor, was defined as the total time \\[per day\\] spent in LVPA at the end of the study minus the baseline value. Baseline is the 7 day period starting on the day of enrolment and ending before randomization. End of study is defined as the period starting on the day of week 14 and prior to the week 16 visit. Deaths are treated as the worst outcome and ordering among deaths is based on last value while alive.", "populationDescription": "Full Analysis Set: All participants that were randomized, regardless of whether treated or not, including participants from investigator sites having wearable activity monitor data collected.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "hours", "timeFrame": "At baseline and at end of study or death before week 16.", "groups": [{"id": "OG000", "title": "Dapa 10mg", "description": "Dapagliflozin 10 mg, given once daily per oral use."}, {"id": "OG001", "title": "Placebo", "description": "Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.19", "lowerLimit": "-0.57", "upperLimit": "0.15"}, {"groupId": "OG001", "value": "-0.15", "lowerLimit": "-0.68", "upperLimit": "0.53"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "For the secondary efficacy endpoint, total time spent in LVPA, the testing hypothesis is\n\n* H0: m(r(A)) = m(r(C)) versus\n* H1: m(r(A)) \u2260 m(r(C)) Where H0 and H1 are the null and alternative hypotheses, respectively, and m(r(A)) and m(r(C)) represent the median of the ranked changes in secondary efficacy endpoint, total time spent in LVPA, from baseline to End of study among patients receiving dapagliflozin (Active) and placebo (Control) treatment, respectively.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.19748", "pValueComment": "Total time spent in LVPA was not tested for statistical significance and the p-value is considered nominal because the test for 6MWD was not statistically significant.", "statisticalMethod": "Rank ANCOVA", "statisticalComment": "Model includes baseline rank of outcome variable as a covariate, treatment group as a factor, and is stratified by T2DM status at randomization.", "paramType": "Hodges-Lehmann median diff. vs placebo", "paramValue": "-0.16", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.55", "ciUpperLimit": "0.22"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0.05", "timeFrame": "Includes data collected on or after date of first dose and up to (including) 30 days following last dose of randomized study drug, and no later than visit 5 (up to day 119). Deaths collected on or after first dose of randomized study drug, up to 119 days.", "description": "For analysis of Adverse Events Safety analysis set is used. Safety analysis set : All randomized participants who received at least one dose of study drug.", "eventGroups": [{"id": "EG000", "title": "Dapa 10mg", "description": "Dapagliflozin 10 mg, given once daily per oral use.", "deathsNumAffected": 3, "deathsNumAtRisk": 156, "seriousNumAffected": 19, "seriousNumAtRisk": 156, "otherNumAffected": 0, "otherNumAtRisk": 156}, {"id": "EG001", "title": "Placebo", "description": "Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use.", "deathsNumAffected": 2, "deathsNumAtRisk": 157, "seriousNumAffected": 23, "seriousNumAtRisk": 157, "otherNumAffected": 0, "otherNumAtRisk": 157}], "seriousEvents": [{"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 157}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 157}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 157}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 157}]}, {"term": "Left ventricular failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 157}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 157}]}, {"term": "Chagas' cardiomyopathy", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}]}, {"term": "Erysipelas", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}]}, {"term": "Sepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}]}, {"term": "Infected skin ulcer", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}]}, {"term": "Multiple organ dysfunction syndrome", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}]}, {"term": "Non-cadiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}]}, {"term": "Hyperglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}]}, {"term": "Iron deficiency anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}]}, {"term": "Skin ulcer haemorrhage", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}]}, {"term": "Skin ulcer", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 157}]}, {"term": "Peripheral ischaemia", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 157}]}, {"term": "Orthostatic hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}]}, {"term": "Upper gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}]}, {"term": "Postoperative thoracic procedure complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 157}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}]}, {"term": "Mediastinal haemorrhage", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 23.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 156}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 157}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "In this study, a subset of participants received wearable activity monitors to wear at home for 3 periods of 7 days. Data collection from the wearable device was challenging and a substantial amount of data was missing. This limits the use of the data based on the wearable activity monitors to investigate the potential impact of study drug on the amount, duration, and intensity of physical activity."}, "certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "\u0141y\u017cwa, Dawid", "organization": "Astrazeneca", "email": "dawid.lyzwa@astrazeneca.com", "phone": "+48 882 345 259"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2020-03-04", "uploadDate": "2021-03-03T09:35", "filename": "Prot_000.pdf", "size": 1728497}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-08-12", "uploadDate": "2021-03-03T09:35", "filename": "SAP_001.pdf", "size": 581450}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2021-03-29", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "C000529054", "term": "Dapagliflozin"}], "ancestors": [{"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M348449", "name": "Dapagliflozin", "asFound": "Intramuscular", "relevance": "HIGH"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}